DIVITUM
LIVE

Serial Number

79344278

Owner

Biovica International AB

Attorney

Mark H. Tidman

Filing Date

Apr 13, 2022

Add to watchlist:

No watchlists yet
View on USPTO

DIVITUM Trademark

Serial Number: 79344278 • Registration: 7129071

DIVITUM is a trademark filed by Biovica International AB on April 13, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Biovica International AB (3 trademarks)

Dag Hammarskjölds väg 54B

Entity Type: 99

Trademark Details

Filing Date

April 13, 2022

Registration Date

August 8, 2023

Published for Opposition

May 23, 2023

Goods & Services

Scientific laboratory services and scientific research and analysis regarding monitoring and predicting treatment response to cancer therapy, and in viral therapy and autoimmune therapy; scientific laboratory services and research and analysis regarding measuring the activity of enzyme in blood serum or cell cultures; research and development in the field of diagnostic preparations; scientific research and development, namely, diagnostic development; data science services, namely, compiling data for research purposes in the field of biostatistics; laboratory biomarker analysis services and related data analysis; biochemical analysis; medical laboratory services; conducting preclinical studies in the nature of scientific feasibility studies; medical laboratory services regarding measurement of cell division; conducting scientific feasibility studies, namely, preclinical studies regarding measurement of cell proliferation; medical laboratory services regarding measurement of enzymatic activity; conducting scientific feasibility studies, namely, preclinical studies regarding measurement of enzymatic activity

Diagnostic agents and reagents, preparations and substances for medical and veterinary purposes for the measurement of cell division; diagnostic agents and reagents, preparations and substances for measuring enzyme activity for medical and veterinary purposes; diagnostic kits comprised of medical diagnostic reagents and biomarker assays to monitor and predict treatment response in cancer therapy; diagnostic kits comprised of medical diagnostic reagents and biomarker assays to monitor and predict treatment response in viral diseases; diagnostic kits comprised of medical diagnostic reagents and biomarker assays to monitor and predict treatment response in autoimmune diseases

Diagnostic preparations for scientific or research use; diagnostic agents and reagents for scientific or research use

Medical, biomedical and veterinary diagnostic monitoring and testing services regarding blood serum or plasma samples or cell cultures; medical, biomedical and veterinary diagnostic monitoring and testing services regarding measurement of cell proliferation; medical, biomedical and veterinary diagnostic monitoring and testing services regarding measurement of enzymatic activity; provision of medical information and advice relating to the use of medical and veterinary diagnostic equipment; medical testing for diagnostic or treatment purposes, namely, conducting tests to identify diseases affecting cell division, cancer, viral and autoimmune diseases; medical analysis regarding the identification and monitoring of cancer, virus and autoimmune diseases and other diseases that cause cell growth for the diagnosis and treatment of persons

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 21, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 3, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 13, 2023 FICS
FINAL DISPOSITION PROCESSED
Nov 13, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 8, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 8, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 8, 2023 R.PR
NOTIFICATION PROCESSED BY IB
May 24, 2023 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 23, 2023 NPUB
PUBLISHED FOR OPPOSITION
May 23, 2023 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 3, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
May 3, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 3, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 20, 2023 CNSA
REFUSAL PROCESSED BY IB
Apr 20, 2023 RFNT
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 14, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 13, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 13, 2023 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 6, 2023 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Apr 6, 2023 ECDR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Apr 6, 2023 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 6, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 6, 2023 REAP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 29, 2023 RFCS
REFUSAL PROCESSED BY MPU
Mar 29, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 3, 2023 RFCR
NON-FINAL ACTION WRITTEN
Feb 2, 2023 CNRT
ASSIGNED TO EXAMINER
Jan 31, 2023 DOCK
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 24, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 24, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 24, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 24, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 24, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 24, 2022 COAR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 10, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 10, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 10, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 10, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 10, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 10, 2022 COAR
NEW REPRESENTATIVE AT IB RECEIVED
Sep 18, 2022 NREP
APPLICATION FILING RECEIPT MAILED
Jul 12, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 8, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 7, 2022 REPR